C14 Enters into Partnership with Tune.FM

New York, NY – August 14, 2024 – (SeaPRwire) – C14, a leading provider of fiat-to-crypto on and off-ramp solutions, has joined forces with Tune.FM, a cutting-edge music NFT trading platform, to release an off-ramp solution for JAM, the native token of the Tune.fm application. This collaboration marks a significant step forward in the integration of […]

Valuufy Established to Transform Sustainable Business and Investing

KYOTO, JAPAN, Aug 14, 2024 – (JCN Newswire via SeaPRwire.com) – Valuufy, a pioneering fintech startup drawn from a decades’ work in measuring and creating sustainable value at Doshisha University’s Value Research Center, has launched with its groundbreaking ValuuCompass, a comprehensive framework set to transform sustainable business practices and sustainability investing by providing a fully […]

Experience Eternal Romance with Exquisite Blue Diamonds

SINGAPORE, Aug 14, 2024 – (ACN Newswire via SeaPRwire.com) – ALUXE, cherished for its unwavering commitment to celebrating love and happiness, is delighted to introduce 8 stunning new additions to its exclusive “Lovers” collection. Originally launched in 2023, this exquisite wedding ring collection now embraces new designs that seamlessly blend timeless elegance with contemporary flair. ALUXE […]

“LEQEMBI” (Lecanemab) Approved for the Treatment of Alzheimer’s Disease in the United Arab Emirates

TOKYO and CAMBRIDGE, Mass., Aug 14, 2024 – (JCN Newswire via SeaPRwire.com) – Eisai Co., Ltd. and Biogen Inc. announced today that the Ministry of Health and Prevention in the United Arab Emirates (UAE) has approved humanized anti-soluble aggregated amyloid-beta (Aβ) monoclonal antibody “LEQEMBI®” (lecanemab) for the treatment of Alzheimer’s disease (AD). Treatment with LEQEMBI […]

中国生物制药(1177.HK)公布2024中期业绩

重点成果 – 期内,集团共有4个创新产品获中国国家药品监督管理局(「NMPA」)批准上市,分别为安得卫(贝莫苏拜单抗注射液)、安柏尼(富马酸安奈克替尼胶囊)、安洛晴(枸橼酸依奉阿克胶囊)和贝乐林(利拉鲁肽注射液),其中3个为国家…

Sino Biopharmaceutical (1177.HK) Announces 2024 Interim Results

Development Highlights – During the reporting Period, four of the Group’s innovative products were approved for marketing by the National Medical Products Administration of China (“NMPA”), namely Andewei (Benmelstobart Injection), Anboni (Unecritinib capsules), Anluoqing (Envonalkib capsules) and Beilelin (Liraglutide Injection), three of which are national category 1 innovative drugs. – In the first half of […]